Checkmarx Provides Codebashing Training and Cybersecurity Curriculum Advisor to the Vilnius Coding School to Train the Next Generation of Developers on Advanced Application Security
Checkmarx announced that it is partnering with the Vilnius Coding School to alert more software developers to the critical need for application security (AppSec). The partnership will use Codebashing to educate the next generation of developers on the best ways to shift everywhere, incorporating AppSec into every phase of the software development lifecycle. This partnership seeks to help meet the increasing demands of the cybersecurity job market and will include online classes that teach coding students:
• An introduction to application security
• Understanding the different components of application security
• How to use application security solutions
• Interactive training on application security and Codebashing
Codebashing is an interactive secure code training platform helping organizations fulfil their security awareness training compliance obligations. It is focused on training software developers, keeping them engaged, challenged and motivated to develop applications with better security awareness. Erez Yalon, VP of Security Research at Checkmarx, will serve as the special advisor to the curriculum of the cyber and application security programs. “The cybersecurity job market is reaching a more mature stage. More companies are aware of the mission-critical nature of application security as part of overall corporate governance,” said Emmanuel Benzaquen, CEO at Checkmarx. “By 2025, there will be 3 ½ million cybersecurity job openings, according to Cybersecurity Ventures research. Working with the Vilnius Coding School, Checkmarx will help train the pipeline of new application developers to come into the market fully equipped to ‘shift everywhere’ to enable robust AppSec for every part of an application at every phase of the software development lifecycle.”
The Vilnius Coding School has five schools in Lithuania, Czech Republic, Ireland and Latvia, and has built an alumni base of 6500 students. "In our development strategy, we have been looking at a global perspective for a long time, from the development path in European countries to offering the most relevant training to people and companies directly from the biggest market players. Therefore, we are very happy about the new partnership with a leading cybersecurity company Checkmarx, with whom we are strengthening the field of cybersecurity training,” said Julija Rimšelė, the founder and head of the international technology career school for adults, the Vilnius Coding School. The partnership comes as the latest addition to Checkmarx’ partners, who span 70 countries, and serves as a powerful foundation to realize the Checkmarx vision of cybersecurity and software security. In sharing application security knowledge and exploring application security career paths, it is Checkmarx’ mission to bring the field of software security to the forefront in the discussion of overall cyber security awareness and readiness.

Checkmarx Provides Codebashing Training and Cybersecurity Curriculum Advisor to the Vilnius Coding School to Train the Next Generation of Developers on Advanced Application Security

Submit
Minalyze receives EUR 350k from Vinnova to further drive the digital transformation of the mining industry.The funding has been awarded within the program âAdvanced and innovative digitalization 2022â. The program is aimed at development of components and system solutions for the benefit of the next generation of industrial digital solutions, and for new products and services to be developed in Sweden. GAEU supported Minalyze in developing the grant proposal to Vinnova.- Our quality policy at GAEU assumes establishing long-lasting cooperation with our Clients. Innovation oriented companies pursue several complementary projects and activities. Our role is to advise them on how to integrate EU funding opportunities into those plans. After a successful application to Horizon Europe, EIC Accelerator, we have now joined forces with Minalyze team to apply for funding from Vinnova. We are very happy for this success, says Tomasz WÄsik, MBA , Partner at GAEU Consulting.- Vinnova funding will further accelerate the development of the new generation of our solutions for the mining industry. We want to deliver what the industry sees as revolutionary but impossible to achieve. Our entrepreneurial and innovative team challenges the status quo and conquers new technological horizons. We recommend GAEU Consulting as trusted and knowledgeable Vinnova funding advisors to all Swedish start-ups, says Annelie LundstrĂśm , CEO at Minalyze.About Minalyze Minalyze is the world leader in XRF core scanning instruments and software for visualization of geological data. What the industry saw as revolutionary but impossible was challenged and conquered by the entrepreneurial and innovative Minalyze team. Read more atÂ  www.minalyze.com About GAEUGAEU Consulting is a leading independent advisor on European Innovation Funding mechanisms, including Horizon Europe, Eurostars, Vinnova, EIT and EIB. GAEU supports innovative companies in implementing their business strategies with EU funding as a propelling force. Read more atÂ  www.gaeu.com Annelie LundstrĂśm Mikael Arthursson Roland VILHELMSSON Jerzy Klimowicz Joanna Szepelak-Frydrych #greentech #smartmining #innovation #eufunding #vinnova #success #greendeal #digitalization #mining

GAEU Consulting on LinkedIn: #greentech #smartmining #innovation #eufunding #vinnova #successâ€¦

Malvern, Pennsylvania, UNITED STATES
NeoCart® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines
MALVERN, Pa., May  24, 2022  (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that it is diversifying its innovative pipeline by introducing a Phase 3, cell therapy platform technology called NeoCart® (autologous chondrocyte-derived neocartilage). Recently, the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to NeoCart® for the repair of full-thickness lesions of the knee cartilage in adults. NeoCart® is a three-dimensional tissue-engineered disc of new cartilage that is manufactured by growing chondrocytes – the cells responsible for maintaining cartilage health – derived from the patient on a unique scaffold. NeoCart® has the potential to accelerate healing and reduce pain by rebuilding a patient’s damaged knee cartilage. It treats pain at the source, creating a similar, functional joint surface as it was before the injury. Ultimately, the goal is to prevent a patient’s progression to osteoarthritis. NeoCart® was acquired as a part of Ocugen’s reverse merger with the original developer of the therapy, Histogenics, in 2019. “We’re excited that NeoCart® has received this RMAT designation, an important regulatory milestone, especially as we view this product as an enabling technology in cell and regenerative therapy for orthopedic indications. Our next step will be working with the FDA to construct the Phase 3 program to bring this innovation to this emerging treatment area,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen, Inc. “People living with articular cartilage lesions literally have holes in their knees that are extremely difficult to heal, and without proper treatment, they’re at high risk of getting osteoarthritis. We believe that NeoCart® offers the potential for an innovative new option where treatments in this area are still limited and results are not optimal.”
The Regenerative Medicine Advanced Therapy (RMAT) designation is part of the 21st Century Cures Act. The program was created to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse or cure a serious condition. Receiving an RMAT designation offers sponsor companies all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with the FDA. Ocugen is working with the FDA to finalize the Phase 3 protocols necessary to advance the clinical development program of NeoCart® required for eventual market authorization. Articular cartilage lesions are a serious and often mobility-limiting condition. When the cartilage is healthy, it makes movement easy, allowing the bones to glide over each other with very little friction, but it can be damaged by injury or normal wear and tear. Cartilage that is damaged can, over time, cause pain and reduce one’s ability to function. Small articular lesions have a limited capacity to self-repair, and full thickness injuries have no ability to naturally heal. There are no blood vessels or nerves to support healing, and as cartilage matures, chondrocytes have limited ability to replicate. Untreated damage eventually can lead to osteoarthritis. Details of the NeoCart® development program will be shared at a future date. About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at  www.ocugen.com  and follow us on  Twitter  and  LinkedIn . Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements about Ocugen’s intention to work with the U.S. Food and Drug Administration (“FDA”) to finalize the Phase 3 protocols necessary to advance the clinical development program of NeoCart® (autologous chondrocyte-derived neocartilage) required for eventual market authorization. Such statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, ability to timely enroll clinical trial participants, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, Ocugen’s ability to utilize accelerated FDA review designations, such as the Regenerative Medicine Advanced Therapy designation, which does not guarantee an accelerated pathway or timeline for regulatory approval of any such product candidates, including NeoCart® (autologous chondrocyte-derived neocartilage), or increase the likelihood of any such approvals, and the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Ocugen Contact:

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

New capabilities in Element Unify increase flexibility and reduce time to value when building data models
April 19, 2022 09:00 AM Eastern Daylight Time
SAN FRANCISCO--( BUSINESS WIRE )-- Element , a leading software provider in IT/OT data management for industrial companies, today announced new functionality for simplified connections, knowledge graph-based modeling, and advanced joins. Together they significantly increase flexibility and speed up model development for organizations seeking to deploy digital twins or pursue industrial transformation. The Connector Portal provides access to pre-built connectors for a range of commonly-used data sources and consuming targets, speeding analytics projects by obviating the need for manually establishing connections. The portal also provides a connector framework that developers can use to easily build their own custom connectors. Unify Graph brings a knowledge graph approach to bear for mapping the complex data environments typical at most enterprises that data teams must operate across. It allows flexible data modeling spanning arbitrary dimensions such as processes, assets, organizations, etc. necessary for quickly building effective digital twins. With Unify Graph Element customers can more easily adopt a “think big, start small, scale fast” approach by starting small and flexibly and incrementally adding more as their needs call for, building upon existing work. The graphs can be queried and explored within Unify or exported for consumption by graph database products such as AWS Neptune or Neo4j. The new Advanced Joins functionality enables users to combine data from various sources based on matching multiple relevant data fields and using matching approaches including fuzzy and contains matching. The fuzzy matching approach is configurable and allows the user to specify a similarity threshold for deciding matches. Advanced Joins speeds the data wrangling effort, gives the modeler a convenient and flexible method for performing useful and tighter joins, reduces record duplication and enables customers to deploy terminology standards for common assets across their business. “The last mile of data in the world of industrials is integration and understanding the specific relationships between IT/OT data across systems,” said Andy Bane , CEO of Element. “The challenge has been figuring out how to centralize it in a way that is fast and scalable across large organizations. Not only do these new capabilities speed model development, but they reduce costs significantly for an enterprise as they seek to use the latest analytic approaches such as digital twins - and we are excited to partner with our customers and begin deploying this for the world of industrials.”
New functionality within Element Unify:
Connector portal
Pre-build connectors for common data sources and consumers
Examples include: Amazon S3, AWS IoT SiteWise, AWS RDS SQL Server, Azure Blog, Azure SQL Database, Ignition, KEPWare
Connector framework to support custom connectors
Unify Graph
Supports local query and visualization and export to graph databases
Advanced joins

Element Announces Connector Portal, Unify Graph, and Advanced Joins to Speed Digital Twin Development

Volta Power Systems operates as an electrical equipment manufacturer. The company specializes in power storage technology, mobile power systems, power generation, storage and distribution, and more. It was founded in 2015 and is based in Holland, Michigan.

Volta Power Systems

 7/11/17 -- Volta Power Systems has partnered with Advanced to bring the first Class B Motorhome featuring an automotive-grade lithium ion system to market .

Volta Power Systems Partners with Advanced RV - Volta Power Systems
Volta Power Systems and Advanced RV bring First Class B Motorhome to Market with Automotive-Grade Lithium Ion Technology.

Other Investors

Advanced, Object-oriented methodology tools. Advanced Software is the developer of GDPro, software that aims to help customers to design, develop, maintain and re-engineer Web-based, Java, C++, IDL, and component-based applications. Sold to Embarcadero Technologies.

Name	Work History	Title	Status
Albert Mayo		Chief Technology Officer	Current
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more

Name	Albert Mayo	Subscribe to see more
Work History		Subscribe to see more
Title	Chief Technology Officer	Subscribe to see more
Status	Current	Subscribe to see more

Wells Fargo Success Story

Professional Services

Platform Overview

Advanced

Executives

Advanced Management Team

2 Team Members

This profile has not been claimed.

Discover the right solution for your team